Top Markets
#1 Black Phoenix Black Phoenix +860.33%
#2 QuantixAI QuantixAI +102.43%
#3 Nesa Nesa +40.53%
#4 MetaDAO MetaDAO +26.53%
#5 Pons Pons +25.86%
#6 LayerZero LayerZero +19.60%
#7 Bedrock Bedrock +18.18%
#8 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +17.02%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +14.96%
#10 SPX6900 SPX6900 +14.67%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Karuna Therapeutics, Inc. Karuna Therapeutics, Inc.

Karuna Therapeutics, Inc.

KRTX
Rang in Aktien #2195
Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc.... Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors. Currently in Phase III clinical trials, KarXT is being evaluated for several indications: the treatment of acute psychosis in schizophrenia patients, the amelioration of central nervous system conditions (including the negative and cognitive symptoms associated with schizophrenia and general psychosis), and the management of dementia-related psychosis. Beyond KarXT, the firm is also advancing a pipeline of other drug candidates that interact with muscarinic receptors. Karuna Therapeutics, Inc. has forged several strategic partnerships, encompassing licensing agreements with Eli Lilly and Company and Zai Lab (Shanghai) Co., Ltd., a patent license with PureTech Health LLC, and drug discovery collaborations with Charles River Laboratories and PsychoGenics, Inc. Established in 2009, the enterprise initially operated under the name Karuna Pharmaceuticals, Inc., before officially adopting its current corporate identity, Karuna Therapeutics, Inc., in March 2019. Its corporate headquarters are located in Boston, Massachusetts.
Aktienkurs
$329.83
Zuletzt synchronisiert: 2024-03-18
Marktkapitalisierung
$9.75B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Karuna Therapeutics, Inc. (KRTX)

Kategorie

Healthcare
Gewinn für Karuna Therapeutics, Inc. (KRTX)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Karuna Therapeutics, Inc. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Karuna Therapeutics, Inc. von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH